Abstract
Positron Emission Tomography (PET) can be used to quantify proteins of interest in the brain, assess the function of these proteins, and quantify cerebral glucose metabolism and blood flow. Its value in neuropsychiatric pharmaceutical drug development is extensive, from the identification of relevant pathophysiology in disease states, to measurement of blood-brain barrier penetration and regional cerebral occupancy of a pharmaceutical agent, to predictions of treatment outcome from a specific pharmacologic intervention in a specific patient. In this paper, we briefly review some basics of brain imaging using PET, and describe its applications to the field of neuropsychiatric pharmaceutical development, including relevant examples from the existing literature. We conclude with a discussion of future developments that will make PET increasingly available and useful for such purposes.
Keywords: Radioligands, investigational new drug, major depressive disorder, Alzheimer Disease, serotonin 1A receptor
Current Radiopharmaceuticals
Title: Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development
Volume: 1 Issue: 1
Author(s): Jeffrey M. Miller, Dileep Kumar, J. John Mann and Ramin V. Parsey
Affiliation:
Keywords: Radioligands, investigational new drug, major depressive disorder, Alzheimer Disease, serotonin 1A receptor
Abstract: Positron Emission Tomography (PET) can be used to quantify proteins of interest in the brain, assess the function of these proteins, and quantify cerebral glucose metabolism and blood flow. Its value in neuropsychiatric pharmaceutical drug development is extensive, from the identification of relevant pathophysiology in disease states, to measurement of blood-brain barrier penetration and regional cerebral occupancy of a pharmaceutical agent, to predictions of treatment outcome from a specific pharmacologic intervention in a specific patient. In this paper, we briefly review some basics of brain imaging using PET, and describe its applications to the field of neuropsychiatric pharmaceutical development, including relevant examples from the existing literature. We conclude with a discussion of future developments that will make PET increasingly available and useful for such purposes.
Export Options
About this article
Cite this article as:
Miller M. Jeffrey, Kumar Dileep, Mann John J. and Parsey V. Ramin, Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development, Current Radiopharmaceuticals 2008; 1 (1) . https://dx.doi.org/10.2174/1874471010801010012
DOI https://dx.doi.org/10.2174/1874471010801010012 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lower Uric Acid Linked with Cognitive Dysfunction in the Elderly
CNS & Neurological Disorders - Drug Targets Pharmacological Effects of Turmeric on Learning, Memory and Expression of Muscarinic Receptor Genes (M1, M3 and M5) in Stress-induced Mouse Model
Current Drug Targets Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature
Current Medicinal Chemistry TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Near-Infrared Spectroscopy (NIRS): A Non-Invasive In Vivo Methodology for Analysis of Brain Vascular and Metabolic Activities in Real Time in Rodents
Current Vascular Pharmacology Dorsal Stream Dysfunction in Children. A Review and an Approach to Diagnosis and Management
Current Pediatric Reviews Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Drug Delivery Systems for Prevention and Treatment of Osteoporotic Fracture
Current Drug Targets HIV Infection and Myocardial Infarction
Current HIV Research Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Anti-Vascular Endothelial Growth Factor Drug Treatment of Diabetic Macular Edema: The Evolution Continues
Current Diabetes Reviews Oleanolic Acid Ameliorates Aβ25-35 Injection-induced Memory Deficit in Alzheimer’s Disease Model Rats by Maintaining Synaptic Plasticity
CNS & Neurological Disorders - Drug Targets Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia
Current Alzheimer Research Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers
Current Alzheimer Research Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Corticosteroids for the Inflammatory Response to Cardiopulmonary Bypass: An Update
Current Pharmaceutical Design